Early trial of BAT4706 aims to find safe dose for advanced cancer patients
NCT ID NCT05148325
First seen Apr 05, 2026 · Last updated May 01, 2026 · Updated 5 times
Summary
This early-phase study tested a new drug called BAT4706 in 28 adults with advanced solid tumors (including melanoma) who had no other standard treatment options. The main goal was to check the drug's safety and find the highest dose that people can tolerate. This is a first step to see if the drug is safe enough for larger studies, not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing cancer hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.